Возможности терапии первичной дисменореи у молодых женщин

Буралкина Н.А., Батырова З.К., Кумыкова З.Х. Возможности терапии первичной дисменореи у молодых женщин. Клинический случай. Гинекология. 2021; 23 (3): 267–269. DOI: 10.26442/20795696.2021.3.200933

________________________________________________

Buralkina NA, Batyrova ZK, Kumykova ZKh. Opportunities of treatment for primary dysmenorrhea in young women. Case report. Gynecology. 2021; 23 (3): 267–269. DOI: 10.26442/20795696.2021.3.200933

Читать PDF

Аннотация

Первичная дисменорея – одна из наиболее частых причин тазовой боли у женщин. Она способна оказывать негативное влияние на качество жизни и мешать повседневной деятельности. Применение комбинированных оральных контрацептивов у молодых женщин, страдающих первичной дисменореей, является эффективным и безопасным методом лечения. Представлен клинический случай эффективного применения комбинированных оральных контрацептивов с дроспиреноном у молодой женщины с первичной дисменореей, сопровождающейся выраженным болевым синдромом, не купирующимся приемом анальгетиков и спазмолитиков и существенно снижающим качество жизни пациентки.

Ключевые слова: первичная дисменорея, женщины, качество жизни, комбинированные оральные контрацептивы, лечение

________________________________________________

Primary dysmenorrhea is one of the most common causes of pelvic pain in women. It can reduce quality of life and interfere with daily activities. The use of combined oral contraceptives in young women with primary dysmenorrhea is an effective and safe treatment option. The article presents a clinical case of the effective use of combined oral contraceptives containing drospirenone in a young woman with primary dysmenorrhea and severe pain syndrome, which is not relieved by analgesics and antispasmodics and significantly reduces the patient's quality of life.

Keywords: primary dysmenorrhea, women, quality of life, combined oral contraceptives, treatment

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Morrow C, Naumburg EH. Dysmenorrhea. Prim Care. 2009;36(1):19-32,vii. DOI:10.1016/j.pop.2008.10.004
2. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104-13. DOI:10.1093/epirev/mxt009
3. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428-41. DOI:10.1097/01.AOG.0000230214.26638.0c
4. Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9:e026186. DOI:10.1136/bmjopen-2018-026186
5. Dawood MM. Dysmenorrhea. Glob Libr Womens Med. 2008;30:154-67. DOI:10.3843/GLOWM.10009
6. Kuhlmann SA, Bergquist PE, Danjoint D, Wall LL. Unmet Menstrual Hygiene Needs Among Low-Income Women. Obstet Gynecol. 2019;133(2):238-44. DOI:10.1097/AOG.0000000000003060
7. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today:
a critical review. Hum Reprod Update. 2015;21(6):762-78. DOI:10.1093/humupd/dmv039
8. Межевитинова Е.А., Абакарова П.Р., Мгерян А.Н. Дисменорея с позиций доказательной медицины. Consilium Medicum. 2014;16(6):83-7 [Mezhevitinova EA, Abakarova PR, Mheryan AN. Dysmenorrhea from the standpoint of evidence-based medicine. Consilium Medicum. 2014;16(6):83-7 (in Russian)].
9. Mrugacz G, Grygoruk С, Sieczyński P, et al. Etiopathogenesis of dysmenorrhea. Med Wieku Rozwoj. 2013;17(1):85-99.
10. Джобаева Э.М., Мандрыкина Ж.А. Дисменорея. Этиопатогенез, дифференциальная диагностика и терапия в практике современного акушера-гинеколога. Акушерство и гинекология. 2012;4(1) [Jobaeva EM, Mandrykina JA. Dysmenorrhea. Etiopathogenesis, differential diagnosis and therapy in the practice of a modern obstetrician-gynecologist. Akusherstvo i ginekologiya. 2012;4(1) (in Russian)].
11. Latthe PM, Champaneria R. Dysmenorrhoea. BMJ Clin Evid. 2014;2014:0183.
12. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician. 2014;89(5):341-6.
13. Koninckx PR, Ussia A, Adamyan L, et al. Primary Dysmenorrhea. J Obstet Gynaecol Can. 2017;39(7):578-9. DOI:10.1016/j.jogc.2017.03.093
14. Ferries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. Obstet Gynecol. 2020;136(5):1047-58. DOI:10.1097/AOG.0000000000004096
15. Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline.
J Obstet Gynaecol Can. 2017 Jul;39(7):585-95. DOI:10.1016/j.jogc.2016.12.023
16. Чушков Ю.В. Лечение дисменореи: современные возможности применения нестероидных противовоспалительных средств. Фарматека. 2011;13(226):31-6 [Chushkov YuV. Dysmenorrhea treatment: modern possibilities of using non-steroidal anti-inflammatory drugs. Pharmateca. 2011;13(226):31-6 (in Russian)].
17. Yui K, Imataka G, Nakamura H, et al. Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Curr Neuropharmacol. 2015;13(6):776-85. DOI:10.2174/1570159x13666151102103305
18. Xu K, Chen L, Fu L, et al. Stressful Parental-Bonding Exaggerates the Functional and Emotional Disturbances of Primary Dysmenorrhea. Int J Behav Med. 2016;23(4):458-63. DOI:10.1007/s12529-015-9504-0
19. Onaka Y, Shintani N, Nakazawa T, et al. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice. Behav Brain Res. 2015;284:131-7. DOI:10.1016/j.bbr.2015.02.013
20. Moldavan M, Cravetchi O, Williams M, et al. Localization and expression of GABA transporters in the suprachiasmatic nucleus. Eur J Neurosci. 2015;42(12):3018-32. DOI:10.1111/ejn.13083
21. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhea. Cochrane Database Syst Rev. 2001;4:CD002120. DOI:10.1002/14651858.CD002120
22. Уварова Е.В., Гайнова И.Г. Дисменорея: современный взгляд на этиологию, патогенез и обоснование лечебного воздействия. Гинекология. 2005;6(3):114 [Uvarova EV, Gainova IG. Dysmenorrhea: a modern view of the etiology, pathogenesis and the rationale for the therapeutic effect. Gynecology. 2005;6(3):114 (in Russian)].
23. Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women. J Pediatr Adolesc Gynecol. 2016;29(2):143-7. DOI:10.1016/j.jpag.2015.08.009
24. Momoeda M, Akiyama S, Yamamoto S, et al. Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study. Int J Womens Health. 2020;12:175-85. DOI:10.2147/IJWH.S242864
25. Sun X, Qian F, He Y, et al. Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study. Adv Ther. 2020;37(2):906-17. DOI:10.1007/s12325-019-01210-2

________________________________________________

1. Morrow C, Naumburg EH. Dysmenorrhea. Prim Care. 2009;36(1):19-32,vii. DOI:10.1016/j.pop.2008.10.004
2. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104-13. DOI:10.1093/epirev/mxt009
3. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428-41. DOI:10.1097/01.AOG.0000230214.26638.0c
4. Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9:e026186. DOI:10.1136/bmjopen-2018-026186
5. Dawood MM. Dysmenorrhea. Glob Libr Womens Med. 2008;30:154-67. DOI:10.3843/GLOWM.10009
6. Kuhlmann SA, Bergquist PE, Danjoint D, Wall LL. Unmet Menstrual Hygiene Needs Among Low-Income Women. Obstet Gynecol. 2019;133(2):238-44. DOI:10.1097/AOG.0000000000003060
7. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today:
a critical review. Hum Reprod Update. 2015;21(6):762-78. DOI:10.1093/humupd/dmv039
8. Mezhevitinova EA, Abakarova PR, Mheryan AN. Dysmenorrhea from the standpoint of evidence-based medicine. Consilium Medicum. 2014;16(6):83-7 (in Russian)
9. Mrugacz G, Grygoruk С, Sieczyński P, et al. Etiopathogenesis of dysmenorrhea. Med Wieku Rozwoj. 2013;17(1):85-99.
10. Jobaeva EM, Mandrykina JA. Dysmenorrhea. Etiopathogenesis, differential diagnosis and therapy in the practice of a modern obstetrician-gynecologist. Akusherstvo i ginekologiya. 2012;4(1) (in Russian)
11. Latthe PM, Champaneria R. Dysmenorrhoea. BMJ Clin Evid. 2014;2014:0183.
12. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician. 2014;89(5):341-6.
13. Koninckx PR, Ussia A, Adamyan L, et al. Primary Dysmenorrhea. J Obstet Gynaecol Can. 2017;39(7):578-9. DOI:10.1016/j.jogc.2017.03.093
14. Ferries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. Obstet Gynecol. 2020;136(5):1047-58. DOI:10.1097/AOG.0000000000004096
15. Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline.
J Obstet Gynaecol Can. 2017 Jul;39(7):585-95. DOI:10.1016/j.jogc.2016.12.023
16. Chushkov YuV. Dysmenorrhea treatment: modern possibilities of using non-steroidal anti-inflammatory drugs. Pharmateca. 2011;13(226):31-6 (in Russian)
17. Yui K, Imataka G, Nakamura H, et al. Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Curr Neuropharmacol. 2015;13(6):776-85. DOI:10.2174/1570159x13666151102103305
18. Xu K, Chen L, Fu L, et al. Stressful Parental-Bonding Exaggerates the Functional and Emotional Disturbances of Primary Dysmenorrhea. Int J Behav Med. 2016;23(4):458-63. DOI:10.1007/s12529-015-9504-0
19. Onaka Y, Shintani N, Nakazawa T, et al. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice. Behav Brain Res. 2015;284:131-7. DOI:10.1016/j.bbr.2015.02.013
20. Moldavan M, Cravetchi O, Williams M, et al. Localization and expression of GABA transporters in the suprachiasmatic nucleus. Eur J Neurosci. 2015;42(12):3018-32. DOI:10.1111/ejn.13083
21. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhea. Cochrane Database Syst Rev. 2001;4:CD002120. DOI:10.1002/14651858.CD002120
22. Uvarova EV, Gainova IG. Dysmenorrhea: a modern view of the etiology, pathogenesis and the rationale for the therapeutic effect. Gynecology. 2005;6(3):114 (in Russian)
23. Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women. J Pediatr Adolesc Gynecol. 2016;29(2):143-7. DOI:10.1016/j.jpag.2015.08.009
24. Momoeda M, Akiyama S, Yamamoto S, et al. Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study. Int J Womens Health. 2020;12:175-85. DOI:10.2147/IJWH.S242864
25. Sun X, Qian F, He Y, et al. Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study. Adv Ther. 2020;37(2):906-17. DOI:10.1007/s12325-019-01210-2

Авторы

Н.А. Буралкина*, З.К. Батырова, З.Х. Кумыкова

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*n_buralkina@oparina4.ru

________________________________________________

Nataliya A. Buralkina*, Zalina K. Batyrova, Zaira Kh. Kumykova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*n_buralkina@oparina4.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.